ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
2Q 2023 ZYNLONTA®1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter…
News
iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates
– Preparation underway with GSK for Phase 3 registrational studies evaluating belrestotug and dostarlimab combination – Initiated…
iTeos Reports Second Quarter 2023 Financial Results and Provides Business Updates
– Preparation underway with GSK for Phase 3 registrational studies evaluating belrestotug and dostarlimab combination – Initiated…
Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023
HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company…
Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023
HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company…
Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
Essential1OLE: Change in mADL11 from Baseline, By Study week Weekly change from week 8 in…
Praxis Precision Medicines Announces Positive Data from Randomized Withdrawal Sub-Study and Long-Term Extension of Essential1 Study for Ulixacaltamide
Essential1OLE: Change in mADL11 from Baseline, By Study week Weekly change from week 8 in…
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Phase 3 PATHFNDR-1 Study Topline Data expected in September 2023 Enrollment Completed in Phase 3…
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Phase 3 PATHFNDR-1 Study Topline Data expected in September 2023 Enrollment Completed in Phase 3…
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the…
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
– On track to dose first participant in ENTR-601-44 Phase 1 clinical trial in the…
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold® Revenue…
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold® Revenue…
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in…
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Established Exclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in…
Monopar Provides Encouraging Camsirubicin Clinical Data Update
WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
Monopar Provides Encouraging Camsirubicin Clinical Data Update
WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
— Agreement Follows Recent Regulatory Approval in Israel of VAZKEPA® to Reduce the Risk of…
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
— Agreement Follows Recent Regulatory Approval in Israel of VAZKEPA® to Reduce the Risk of…
InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update
– Completed transformational private placement for up to $113.6 million, including $42.2 million upfront –…